R‐CHOP treatment for patients with advanced follicular lymphoma: Over 15‐year follow‐up of JCOG0203
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19213 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Takashi Watanabe und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Lymphoma, Follicular. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Clinical Cancer Research, Grants-In-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan, National Cancer Center Research and Development Fund.
Abstract (Originalsprache)
Anti‐CD20 antibody in combination with chemotherapy extends overall survival (OS) in untreated advanced‐stage follicular lymphoma (FL), yet the optimal associated therapy is unclear. Data on the cumulative incidence of secondary malignancies postrelapse after conventional immunochemotherapy are scarce. A long‐term analysis of rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) as first‐line treatment was conducted in a randomised clinical trial. A six‐cycle R‐CHOP regimen was administered every 2 or 3 weeks without rituximab maintenance. A prespecified evaluation was conducted 15 years after the completion of enrolment, following initial analysis results that showed no significant differences in outcomes at the 3‐year mark. In‐depth analyses were performed on the cohort of 248 patients with FL who were allocated to the two treatment arms. With a median follow‐up period of 15.9 years, the 15‐year OS was 76.2%. There were no protocol treatment‐related deaths, nor were there any fatal infections attributable to subsequent lymphoma treatment. At 15 years, the cumulative incidence of non‐haematological and haematological malignancies was 12.8% and 3.7% respectively. Histological transformation appeared after a median of 8 years. R‐CHOP maintains safety and efficacy in patients with advanced FL over extended follow‐up, making it a viable first‐line option for patients with advanced‐stage FL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Haematology, National Cancer Center Hospital, Tokyo, Japan.
- JCOG Data Center/Operation Center, National Cancer Center, Tokyo, Japan.
- Department of Haematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.
- Department of Haematology, Saitama Cancer Center, Saitama, Japan.
- Department of Haematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Haematology and Oncology, Shiga General Hospital, Moriyama, Japan.
ORCID-Profile: Takashi Watanabe, Dai Maruyama, Kazuyuki Shimada, Junya Kuroda, Hirokazu Nagai
Förderung
- Clinical Cancer Research
- Grants-In-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan
- National Cancer Center Research and Development Fund
Zitieren
APA
Watanabe, T., Tobinai, K., Wakabayashi, M., Maruyama, D., Yamamoto, K., Kubota, N., Shimada, K., Asagoe, K., Yamaguchi, M., Ando, K., Ogura, M., Kuroda, J., Suehiro, Y., Matsuno, Y., Tsukasaki, K., & Nagai, H. (2024). R‐CHOP treatment for patients with advanced follicular lymphoma: Over 15‐year follow‐up of JCOG0203. British Journal of Haematology. https://doi.org/10.1111/bjh.19213
Vancouver
Watanabe T, Tobinai K, Wakabayashi M, Maruyama D, Yamamoto K, Kubota N, et al. R‐CHOP treatment for patients with advanced follicular lymphoma: Over 15‐year follow‐up of JCOG0203. British Journal of Haematology. 2024. doi:10.1111/bjh.19213
BibTeX
@article{Watanabe2024,
author = {Watanabe, Takashi and Tobinai, Kensei and Wakabayashi, Masaki and Maruyama, Dai and Yamamoto, Kazuhito and Kubota, Nobuko and Shimada, Kazuyuki and Asagoe, Kohsuke and Yamaguchi, Motoko and Ando, Kiyoshi and Ogura, Michinori and Kuroda, Junya and Suehiro, Youko and Matsuno, Yoshihiro and Tsukasaki, Kunihiro and Nagai, Hirokazu},
title = {R‐CHOP treatment for patients with advanced follicular lymphoma: Over 15‐year follow‐up of JCOG0203},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19213}
}
EUVIMED